The benefits of screening all COVID-19 pneumonia patients at the time of admission for hyperglycemia
The results from a lately published study by Laurenzi et al. strongly support the need to screen hyperglycemia from all patients who are hospitalized due to COVID-19 pneumonia. Good glycemic control has been shown to reduce disease severity and COVID-19 mortality for patients with hyperglycemia. Early detection and treatment of COVID-associated hyperglycemia may greatly benefit these patients.
The study compared the clinical characteristics, laboratory findings and major outcomes of patients who were hospitalized due COVID-19 pneumonia with COVID-associated hyperglycemia or pre-existing diabetes. Patients with COVID-associated hyperglycemia had lower BMI, significantly less comorbidities and higher level of inflammatory markers and indicators of multi-organ injury compared to patients with pre-existing diabetes. They also had poorer clinical outcomes and a delayed viral clearance compared to pre-existing diabetes. Once the viral infection was resolved, COVID-associated hyperglycemia reversed in most patients. The study concluded that recognition of hyperglycemia is relevant for early and appropriate patient management and close monitoring for the progression of disease severity.
- Laurenzi et al., Pre-Existing Diabetes and COVID-Associated Hyperglycaemia in Patients with COVID-19 Pneumonia, Biology 2021, 10(8), 754; https://www.mdpi.com/2079-7737...